Scancell Holdings, the developer of novel immunotherapies for the treatment of cancer and infectious disease, has expanded its R&D capabilities by taking new laboratory and office space in the Bellhouse Building at Oxford Science Park.
The new premises, which Scancell said were complementary to its laboratories in the Biodiscovery Institute at the University of Nottingham, will allow the firm to accelerate the development of its portfolio of immunotherapies.
Scancell, which raised £46m last year to drive its pipeline through clinical trials, is now working from 1,900 sq ft of laboratory space and 1,800 sq ft of office facilities at Oxford Science Park. Scancell currently employs just over 40 staff, of which approximately half are located in the new premises, and plans to recruit additional people to its clinical and product development teams in the next 12 months.
The new laboratories will support the company’s clinical trial activities and provide analytical and formulation facilities for future product development.
Professor Lindy Durrant, chief executive of Scancell, said: “Oxford Science Park is the perfect location for Scancell’s expansion, with access to an excellent local talent pool as we grow the business. We are excited to be part of the creative and collaborative group of companies located in the park and look forward to further developing our innovative products at this new site.”
Oxford Science Park chief executive Rory Maw said Scancell’s expansion to the park was “a great addition to the innovation community here”.
Earlier this month Singaporean sovereign wealth fund GIC bought a 40% stake in Oxford Science Park from owner Magdalen College for £160m. The stake sale will help fund development at the park.
To send feedback, e-mail samantha.mcclary@eg.co.uk or tweet @samanthamcclary or @EGPropertyNews
